(2R,5S)-7-methyl-2-[4-methyl-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-yl]-6-oxo-1,7-diazaspiro[4.4]nonane-1-carboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: (2R,5S)-7-methyl-2-[4-methyl-6-[4-(trifluoromethyl)phenyl]pyrimidin-2-yl]-6-oxo-1,7-diazaspiro[4.4]nonane-1-carboxylic acid
• 化学式: C₂₁H₂₁F₃N₄O₃
• 分子量: 434.4
• InChiKey: NWYXZFRYRGNEKU-UZLBHIALSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  31
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  86.6
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• [EN] Novel Compounds<br/>[FR] NOUVEAUX COMPOSÉS
  申请人：CONVERGENCE PHARMACEUTICALS

  公开号：WO2013175205A1

  公开（公告）日：2013-11-28

  NOVEL COMPOUNDS The invention relates to spiro derivatives, to the use of said derivatives intreating diseases and conditions mediated by modulation of voltage-gated sodium channels, to compositions containing said derivatives and processes for their preparation.

  新化合物。本发明涉及螺环衍生物，涉及使用该衍生物治疗通过调节电压门控钠通道介导的疾病和症状，涉及含有该衍生物的组合物和其制备方法。
• NOVEL COMPOUNDS
  申请人：CONVERGANCE PHARMACEUTICALS LIMITED

  公开号：US20150119404A1

  公开（公告）日：2015-04-30

  The invention relates to spiro derivatives, to the use of said derivatives in treating diseases and conditions mediated by modulation of voltage-gated sodium channels, to compositions containing said derivatives and processes for their preparation.

  本发明涉及螺环衍生物，其在治疗通过调节电压门控钠通道介导的疾病和病状中的应用，以及含有该衍生物的组合物和其制备过程。
• Novel Pyrimidinyl-DiazoSpiro Compounds
  申请人：CONVERGENCE PHARMACEUTICALS LIMITED

  公开号：US20160184306A1

  公开（公告）日：2016-06-30

  The invention relates to spiro derivatives, to the use of said derivatives in treating diseases and conditions mediated by modulation of voltage-gated sodium channels, to compositions containing said derivatives and processes for their preparation.

  本发明涉及螺内酯衍生物，涉及使用该衍生物治疗通过调节电压门控钠通道介导的疾病和病症，涉及含有该衍生物的组合物以及其制备方法。
• Pyrimidinyl-diazospiro compounds
  申请人：CONVERGENCE PHARMACEUTICALS LIMITED

  公开号：US10010551B2

  公开（公告）日：2018-07-03

  The invention relates to spiro deriviatives, to the use of said derivatives in treating diseases and conditions mediated by modulation of voltage-gated sodium channels, to compositions containing said derivatives and processes for their preparation.

  本发明涉及螺衍生物、上述衍生物在治疗通过调节电压门控钠通道介导的疾病和病症中的用途、含有上述衍生物的组合物及其制备工艺。
• 7-Methyl-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one
  申请人：Convergence Pharmaceuticals Limited

  公开号：EP2861602B1

  公开（公告）日：2016-08-10